Genetic Analysis AS (FRA:8V8) GF Value Rank: 5 (As of Aug. 13, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8V8 Genetic Analysis AS FRA:8V8
34 GF Score
Price €0.04
GF Value €0.02
! 4 Warning Signs
View Full Analysis

What is Genetic Analysis AS GF Value Rank?

Genetic Analysis AS FRA:8V8 34 GF Value Rank is 5 as of Aug. 13, 2026, which is at its 10-year median of 5.00. GuruFocus rates FRA:8V8 with a GF Score™ of 34/100 and a GF Value™ of €0.02. The stock has 4 warning signs investors should review.

Genetic Analysis AS has the GF Value Rank of 5.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Genetic Analysis AS GF Value Rank Related Terms


FRA:8V8 vs TMO, DHR, IDXX: GF Value Rank Comparison

For the Diagnostics & Research subindustry, Genetic Analysis AS's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS GF Value Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's GF Value Rank falls into.


FRA:8V8
34GF Score
Genetic Analysis AS FRA:8V8
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 5 mean?
Genetic Analysis AS (FRA:8V8) has a GF Value Rank of 5 as of Aug. 13, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Genetic Analysis AS and its competitors. This is near median its historical median of 5.00. Over the past decade, Genetic Analysis AS's GF Value Rank has ranged from 4.00 to 10.00.
Is Genetic Analysis AS's GF Value Rank too high?
Genetic Analysis AS's current GF Value Rank of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Genetic Analysis AS has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's GF Value Rank compare to TMO and DHR?
Genetic Analysis AS's GF Value Rank of 5 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Genetic Analysis AS's own GF Value Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Diagnostics & Research company?
A good GF Value Rank depends on the Medical Diagnostics & Research industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current GF Value Rank is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current GF Value Rank of 5. The stock's GF Value™ is €0.02, compared to a current price of €0.04 — trading 119% above its estimated fair value. The current GF Value Rank is 5, which is near median its 10-year median of 5.00. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current GF Value Rank is 5 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued. The current stock price of €0.04 is trading 119% above its estimated GF Value™ of €0.02.

Key valuation signals for FRA:8V8:

  • GF Value Rank: 5 (near median its 10-year median of 5.00)
  • GF Value™: €0.02 vs. price of €0.04 (119% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genetic Analysis AS Business Description

Other Exchanges GEAN:Sweden
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score

Get the complete analysis for FRA:8V8

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€0.02
GF Value